Back to top
more

Insulet (PODD)

(Delayed Data from NSDQ)

$332.13 USD

332.13
812,069

-8.16 (-2.40%)

Updated Sep 16, 2025 04:00 PM ET

After-Market: $330.81 -1.32 (-0.40%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Compared to Estimates, Insulet (PODD) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Insulet (PODD) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stay Ahead of the Game With Insulet (PODD) Q4 Earnings: Wall Street's Insights on Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.

Zacks Equity Research

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FXH

Zacks Equity Research

Zacks.com featured highlights NVIDIA, AppLovin and Insulet

by Zacks Equity Research

NVIDIA, AppLovin and Insulet have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

NVIDIA & 2 Other Profitable Stocks to Buy in February

by Tirthankar Chakraborty

NVIDIA, AppLovin and Insulet have been selected as the top picks with a high net income ratio.

Zacks Equity Research

Is Omnicell Stock a Solid Pick for Your Portfolio Right Now?

by Zacks Equity Research

OMCL stays on investors' radar due to the strong performance of the Advanced Services portfolio.

Zacks Equity Research

DGX Stock Dips Despite Q4 Earnings and Revenue Beat, Margins Rise

by Zacks Equity Research

Quest Diagnostics' fourth-quarter 2024 performance benefits from the strength of its core business.

Zacks Equity Research

SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 50% and 10.55%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is QIAGEN Stock an Apt Pick for Your Portfolio Right Now?

by Zacks Equity Research

QGEN stays on investors' radar due to its robust expansion of testing menu and benefits from strategic ties.

Zacks Equity Research

Here's Why You Should Add PODD Stock to Your Portfolio Now

by Zacks Equity Research

Insulet stays on investors' radar owing to its solid progress with Omnipod 5 and strong solvency position.

Zacks Equity Research

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

by Zacks Equity Research

Sector ETF report for FXH

Zacks Equity Research

GEHC or PODD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GEHC vs. PODD: Which Stock Is the Better Value Option?

Zacks Equity Research

PODD Stock Gains From the Launch of Omnipod 5 in Five Countries in EU

by Zacks Equity Research

Insulet announces the launch of Omnipod 5 in five more countries in Europe, Italy, Denmark, Finland, Norway and Sweden.

Zacks Equity Research

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

GEHC vs. PODD: Which Stock Is the Better Value Option?

by Zacks Equity Research

GEHC vs. PODD: Which Stock Is the Better Value Option?

Zacks Equity Research

Why Insulet (PODD) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

RMD or PODD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

RMD vs. PODD: Which Stock Is the Better Value Option?

Zacks Equity Research

Should You Continue to Retain Insulet Stock in Your Portfolio Now?

by Zacks Equity Research

PODD stock stays on investors' radar owing to its solid progress with Omnipod 5 and robust potential in the diabetes market.

Zacks Equity Research

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FXH

Zacks Equity Research

Here's Why Insulet (PODD) is a Strong Growth Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

If You Invested $1000 in Insulet a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Zacks Equity Research

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

by Zacks Equity Research

Sector ETF report for FXH

Zacks Equity Research

PODD Stock to Gain From Launch of Omnipod 5 With Abbott's CGM in US

by Zacks Equity Research

Insulet's Omnipod 5 System is now compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the United States.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.